ArticleNPJ systems biology and applications2025
Modeling the metabolic response of A2780 ovarian cancer cells to gold-based cytotoxic drugs.
Article in NPJ systems biology and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Dual-Action Gold(I) Prodrug Targeting Redox Homeostasis and Extracellular Matrix Remodeling in Ovarian Cancer.ACS medicinal chemistry letters · 2026Article
- Noble Metal Complexes and Non-Canonical Nucleic Acids: From G-Quadruplex Recognition to Emerging Functional Architectures.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gold compounds are a promising class of experimental anticancer metallodrugs. Unlike platinum-based drugs, their antiproliferative effects are thought to result mainly from modulation of cancer cell metabolism rather than direct interaction with DNA. Previous NMR studies have shown that four cytotoxic gold compounds - auranofin, aurothiomalate and two gold N-heterocyclic carbenes - induce distinct metabolic changes in A2780 ovarian cancer cells, suggesting the occurrence of different mechanisms of action. To better understand these effects, we constructed a genome-scale metabolic model (GEM) of A2780 cells to analyze the NMR-detected metabolomic changes. The model successfully predicts the diverse metabolic responses induced by each gold compound and identifies common metabolic changes. These results confirm the potential of GEMs as a powerful tool for interpreting and predicting cellular responses to gold-based drugs, providing insights into their mechanisms of action and potential therapeutic applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.